We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New Test to Detect T-Cell Immune Response to SARS-CoV-2 Using AI-Powered Platform Delivers Results in Real-Time

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Hyris Test quickly detects T-Cell response to SARS-CoV-2 (Photo courtesy of Hyris Ltd.)
Image: Hyris Test quickly detects T-Cell response to SARS-CoV-2 (Photo courtesy of Hyris Ltd.)

A new test to detect T-cell immune response to SARS-CoV-2 leverages the power of an AI-powered platform that enables genetic testing in any setting, at any time, with results available in real-time.

Hyris Ltd. (London, UK) has developed the rapid T-Cell test to track patients' immunity levels to SARS-CoV-2 for global clinical and research use after having inked an exclusive licensing agreement with the Duke-NUS Medical School (Singapore). This new solution leverages the power of the renowned HYRIS bCUBE and the whole Hyris System. This disruptive platform enables genetic testing in any setting, at any time, with results available in real-time through its AI-powered platform.

The Hyris System, Hyris' proprietary genetic testing platform, is an ideal Point of Care solution in the fight against COVID-19. Thanks to the power of the extremely portable proprietary hardware HYRIS bCUBE, the Hyris System works anywhere and at any time, successfully detecting the presence of coronavirus on surfaces and environments (the SARS-CoV-2 Environmental test) and COVID-19 infection in individuals (SARS-CoV-2 Human test), including all the main variants of concern that have emerged since July 2020.

The T-Cell clinical test kit developed through an exclusive licensing agreement between Hyris and Duke-NUS Medical School allows rapid and large-scale expansion of studies to track T-cell activity across the world while not requiring specialized or expensive equipment. The simple and rapid method to measure T-cell immune response to the SARS-CoV-2 virus helps to define the correlates of protection from T Cells and antibodies for the development of COVID-19 vaccines. Such a test is a prime example of how scientific innovation is the key to the fight against the SARS-CoV-2 virus in order to boost population immunity.

"Alongside with limiting the spread of SARS-CoV-2 new variants and potential hotspots, getting high immunity rates among populations is number one priority for policymakers and health institutions," said Stefano Lo Priore, Founder and CEO at Hyris. "Hyris integrated its solutions with a simple yet effective test, to measure a patient T-cell immune response to the SARS-CoV-2 virus, which causes COVID-19."

Related Links:
Hyris Ltd. 
Duke-NUS Medical School

Gold Supplier
SARS-CoV-2 Rapid Antigen Test
GLINE-2019-nCoV Rapid Antigen Test
Tuberculosis (TB) Test
QIAreach QuantiFERON-TB
Malaria Molecular Detection System
HumaLoop M
Assayed Hemoglobin Control

Print article


Clinical Chem.

view channel
Image: Illustration is of the Vertical Auto Profile (VAP) Lipid test with clear demarcation of the different lipoprotein classes and subclasses. (Photo courtesy of VAP Diagnostics Laboratory)

Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients... Read more

Molecular Diagnostics

view channel
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)

Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. These gene fusions can drive tumorigenesis by altering gene expression and activity.... Read more


view channel
Image: Blood smear from a patient with low grade follicular lymphoma in leukemic phase: note cleaved nuclei (coffee bean cells) and scant cytoplasm (Photo courtesy of Kyle Bradley, MD)

Classification of Mature B-Cell Neoplasms Employing Standardized Flow Cytometry

The classification of lymphoid neoplasms integrates clinical, pathological, immunophenotypic, genetic, and molecular data in order to distinguish between mature B-cell lymphoma entities.... Read more


view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more


view channel

Roche Introduces AI-Based Digital Pathology RUO Algorithms for Evaluation of Breast Cancer Markers

Roche (Basel, Switzerland) has announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.